Management of Periocular Eczema

Introduction to Treatment Guidelines

The American Academy of Dermatology recommends against the use of oral corticosteroids for chronic atopic dermatitis management, due to the risk of severe rebound dermatitis upon discontinuation 1
The American Academy of Dermatology guidelines do not recommend oral corticosteroids as a standard treatment option for atopic dermatitis 1

Topical corticosteroids are recommended as first-line treatment for eczema affecting the eyelids and periocular area, with Class V/VI corticosteroids (such as hydrocortisone 2.5%) preferred for facial and eyelid application 2, 3
Topical corticosteroids should be applied several times daily to the eyelids, then tapered once inflammation is controlled 2
Loteprednol etabonate or fluorometholone phosphate may be considered for periocular use due to their limited ocular penetration and lower risk of increased intraocular pressure and cataract formation 2
Topical cyclosporine may be helpful in some patients with eyelid involvement 2

For severe, extensive atopic dermatitis (>20-30% body surface area) that includes periocular involvement, prednisone 0.5-1 mg/kg/day may be used for a minimum duration of 2-3 weeks with gradual taper to prevent rebound dermatitis 4, 5
The American Academy of Dermatology recommends dupilumab or tralokinumab (biologics) as preferred systemic therapies for severe atopic dermatitis, with high-certainty evidence for efficacy 1
Cyclosporine at 3-5 mg/kg/day is an option for severe cases, though limited to 1 year of use 1

Oral corticosteroids should not be prescribed for less than 2 weeks, as this leads to rebound dermatitis 4
Long-term or chronic intermittent systemic corticosteroids should be avoided for any dermatologic condition 5
High-potency topical steroids should not be used on the face or eyelids, as this increases the risk of skin atrophy and ocular complications 2, 3
Patients should be monitored for corticosteroid-induced complications, including increased intraocular pressure, cataract formation, and skin atrophy 2